Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Pancreatic Neoplasms 3Wilms Tumor 1Small Bowel Adenocarcinoma 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Ovarian Neoplasms 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Neoplasms 1Hepatoblastoma 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1Advanced Rectal Cancer 1

Interventions

Bevacizumab 19Paclitaxel 16Carboplatin 12pembrolizumab 11liposomal doxorubicin 10Cyclophosphamide 9Specimen Handling 8Gemcitabine 8olaparib 7fludarabine 7Topotecan 7Magnetic Resonance Spectroscopy 7Taxes 5Immunoglobulin G 5Fulvestrant 5Disulfides 5niraparib 4Oxaliplatin 4Nivolumab 4Biopsy 4trastuzumab deruxtecan 3palbociclib 3mirvetuximab soravtansine 3aldesleukin 3Leucovorin 3Fluorouracil 31-dodecylpyridoxal 3ulixertinib 2nilotinib 2ipatasertib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Neoplasms × irinotecan sucrosofate × 30 days × Clear all
NCT07591831 2026-05-18

Liposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Not yet recruiting
30 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡